Altimmune Inc. (Nasdaq: $ALT) Stock Hub: PERFORMA Phase 3 Under Way and $519 Million in the Bank

01 Latest development: PERFORMA Phase 3 begins enrolling patients in MASH

On August 3, 2026, before the U.S. market open, Altimmune announced that it has begun enrolling patients in the PERFORMA Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis. This is the single most important operational milestone the company had outstanding: PERFORMA is the registrational study on which the MASH opportunity depends, and its start converts a guided plan into an active pivotal program.

PERFORMA is a global, randomized, double-blind, placebo-controlled, parallel-group study in adults with MASH and confirmed moderate to advanced liver fibrosis (F2–F3). It follows the IMPACT Phase 2b results and, according to the company, incorporates feedback from both the FDA and European regulatory agencies. The 52-week data readout is anticipated in 2029.

Three design choices that matter

First, the trial is event-driven with an interim analysis intended to support accelerated approval, and it is Cohort 1 that carries the accelerated-approval endpoint on biopsy at 52 weeks. That structure is what allows a histology-based route to market to open years before the long-term outcomes analysis at roughly 60 months completes. The company has not separately detailed the timing of the interim analysis. It therefore remains an inference, not disclosed guidance, that the accelerated-approval step and the 52-week biopsy analysis sit together, ahead of the outcomes phase.

Second, the study uses a simple one- or two-step monthly dose titration from 1.2 mg up to the 1.8 mg or 2.4 mg trial doses. Titration is the standard tool for improving tolerability with incretin-class therapies, and its inclusion signals that the company is trying to protect adherence and dropout rates in a long biopsy-driven study. Note that the 2.4 mg dose being carried into Phase 3 is the same strength that produced the positive RECLAIM result in alcohol use disorder, while IMPACT Phase 2b tested 1.2 mg and 1.8 mg.

Third, PERFORMA will use the FDA-qualified AIM-MASH AI Assist tool to help standardize histological assessment of liver biopsy samples. Reader variability in MASH histology has been a recurring source of noise across the field, and reducing it is directly relevant to the one endpoint that has been the weakest part of the Altimmune dataset so far: conventional fibrosis scoring, which was numerically favorable but not statistically significant at Week 24 in IMPACT.

Chief Medical Officer Christophe Arbet-Engels framed the start around the balanced one-to-one glucagon/GLP-1 receptor agonism providing direct liver effects alongside metabolic benefits. Chief Executive Officer Jerry Durso pointed to the pace of execution, noting that the company went from securing funding for PERFORMA to initiating the trial in three months, and connected the milestone to the recently announced positive RECLAIM Phase 2 data in AUD. Naim Alkhouri of Summit Clinical Research, a principal investigator on the trial, described the objective as testing whether the broad improvements seen in earlier studies translate into meaningful outcomes for a larger MASH population.

What this changes, and what it does not

What changes is the risk profile of the timeline. Before August 3, a slipped Phase 3 start was a live risk that would have pushed the entire valuation bridge to the right. That specific risk is now retired. The two disclosed cohorts also add up to roughly 1,790 patients, which gives a concrete sense of the cost and operational scale ahead.

What does not change is the evidentiary burden. Enrolling a trial is not the same as completing one, and the biopsy-based primary endpoint at 52 weeks remains the test that IMPACT did not fully pass on conventional fibrosis scoring. Enrollment across two cohorts of this size in a competitive MASH landscape will take time, cost money and compete with other sponsors for the same sites and patients. The relevant monitoring questions from here are enrollment pace, site activation, dropout, the timing and design of the interim analysis, and whether quarterly cash burn rises in line with expectations as the program scales.

02 July 28, 2026: RECLAIM reaches its primary endpoint in alcohol use disorder

On July 28, 2026, Altimmune reported that pemvidutide 2.4 mg significantly reduced heavy drinking days compared with placebo in the RECLAIM Phase 2 trial. The study enrolled 100 adults with moderate or severe alcohol use disorder who were overweight or had obesity and treated them once weekly for 24 weeks. The result establishes that the program was not merely a mechanistic extension of the MASH story: pemvidutide has now produced a positive controlled clinical signal in a behavioral-addiction indication.

The company said it plans to seek a meeting with the U.S. Food and Drug Administration to discuss the next development steps. That meeting becomes the immediate regulatory bridge. It should clarify whether Altimmune can advance directly toward a larger registrational program, which endpoint structure the FDA prefers, how much replication will be required and whether future studies must broaden enrollment beyond the overweight-or-obese population tested in RECLAIM.

The positive headline came with the numbers attached. The July 28, 2026 release, filed as Exhibit 99.1 to the Form 8-K, carries both the efficacy and the safety table in full. Heavy drinking days per week at 24 weeks fell by 2.75 on placebo and by 4.20 on pemvidutide, an LS mean difference of 1.45 with p=0.0014. Two secondary endpoints the FDA recognises as registrational were met: a two-level reduction in WHO risk drinking levels in 64.4% of patients (29 of 45) against 34.8% on placebo (16 of 46), odds ratio 3.31, p=0.0049; and zero heavy drinking days between weeks 21 and 24 in 42.2% (19 of 45) against 17.4% (8 of 46), odds ratio 3.84, p=0.0066. Days of abstinence rose 38.9% against 20.5%, a difference of 18.4 points, p=0.0075. The objective check held: serum PEth moved +22.0 on placebo and -153.4 on pemvidutide, a difference of -175.3 with p<0.0001. Body weight fell 9.1% placebo-adjusted, p<0.0001, with no evidence of plateauing. The principal investigator is Henry Kranzler of the University of Pennsylvania.

The safety table covers 50 patients per arm, placebo first. Serious adverse events 1 (2%) against 2 (4%); severe events 3 (6%) against 6 (12%); nausea 24% against 44%; vomiting 6% against 18%; diarrhoea 10% against 20%; constipation 6% against 26%. Treatment discontinuations were 22% on placebo against 20% on pemvidutide, but discontinuations attributed to the study drug were 0% against 10%, five patients, two for vomiting and one each for constipation, fatigue and a haemorrhoid flare. One serious adverse event, hyponatraemia, was judged possibly treatment-related by the investigator. The company attributes the tolerability to a two-step titration to the 2.4 mg dose.

What the numbers do not settle is a different question from whether they exist. RECLAIM randomised 100 patients over 24 weeks; it is a Phase 2, and its endpoints, effect sizes and safety profile still have to hold in a larger and longer registrational programme before they support an approval.

03 Executive summary

Altimmune is best understood as a pemvidutide company rather than a diversified biotechnology platform. Pemvidutide is an investigational once-weekly peptide with balanced 1:1 glucagon and GLP-1 receptor agonist activity. The GLP-1 component is intended to support appetite suppression, weight loss and potentially reward-pathway effects, while the glucagon component is designed to provide liver-directed metabolic activity. This dual profile supports a development strategy spanning metabolic dysfunction-associated steatohepatitis, alcohol use disorder and alcohol-associated liver disease.

The last week of July and the first week of August 2026 reshaped the story twice. The RECLAIM result on July 28 materially changed the clinical picture. Before the readout, AUD was optionality: scientifically interesting, strategically coherent, but clinically unproven. After the readout, pemvidutide has met a prospectively defined Phase 2 primary endpoint in a second disease area. That does not diversify Altimmune at the molecule level—every major program still depends on pemvidutide—but it does diversify the clinical thesis and creates a possible development route beyond MASH.

The flagship opportunity remains MASH. IMPACT Phase 2b produced a strong result on MASH resolution without worsening fibrosis, large reductions in liver fat, clinically relevant weight loss and a favorable adverse-event discontinuation profile. The principal caveat is fibrosis by conventional histology: the standard Week 24 fibrosis-improvement endpoint was numerically better than placebo but did not reach statistical significance. Longer-duration non-invasive markers and qFibrosis digital pathology strengthen the biological argument, but they remain supportive rather than a substitute for the registrational package.

PERFORMA Phase 3 is therefore still the primary valuation bridge, and as of August 3, 2026 that bridge is under construction rather than on paper. The company has begun enrolling the multinational registrational study, with approximately 990 patients in a biopsy-based cohort designed to support accelerated approval and approximately 800 patients in a second cohort identified through non-invasive tests. The 52-week readout remains anticipated in 2029, with final approval expected to rest on liver-related events at approximately 60 months. The RECLAIM win can improve strategic leverage and potentially attract partnering interest, but it does not reduce the execution burden of a program of this size. Management must now advance three related but operationally distinct programs without allowing the new AUD opportunity to dilute focus or accelerate spending beyond the company’s runway assumptions.

The balance sheet became substantially stronger after the April 2026 financing. Altimmune reported approximately $535 million in cash, cash equivalents and short-term investments as of April 30, 2026, including the net proceeds from the offering, and said at the time that this should fund operations through the anticipated 52-week Phase 3 MASH data readout. The Form 10-Q for the quarter ended June 30, 2026 puts it more narrowly: sufficient to fund operations for at least twelve months from the date the financial statements were issued. The financing also sharply increased the share-equivalent base through common shares, pre-funded warrants and 75 million accompanying warrants. Capital availability is a major strength; dilution and warrant supply remain major valuation constraints.

The updated framework is no longer simply “MASH execution versus financing risk.” It is now a four-part test: PERFORMA enrollment pace and interim-analysis execution, regulatory interpretation of the RECLAIM result, full-data quality in AUD, and disciplined use of the strengthened balance sheet. The constructive case has improved because a second controlled trial has succeeded and the pivotal program has actually started. The cautious case remains substantial because RECLAIM is a 100-patient Phase 2 and its effect sizes still have to reproduce at registrational scale, Phase 3 MASH translation is unresolved and Altimmune remains dependent on one investigational molecule.

04 Updated catalyst map after the PERFORMA initiation

Reported August 3, 2026 — PERFORMA Phase 3 enrolling

The registrational MASH study has begun enrolling across two cohorts of approximately 990 and 800 patients. The start removes the risk of a delayed pivotal launch and sets the operational clock toward the anticipated 2029 readout.

Reported July 28, 2026 — RECLAIM primary endpoint met

Pemvidutide 2.4 mg produced a statistically significant reduction in heavy drinking days compared with placebo. This converts AUD from an unproven option into a clinically supported development pillar, subject to full-data review.

Next — FDA meeting on the AUD path

Altimmune plans to discuss next steps with the FDA. The key questions are registrational design, endpoint hierarchy, required number of studies, population breadth, duration and the role of PEth or other objective biomarkers.

Ongoing — PERFORMA enrollment and site activation

Enrollment pace across roughly 1,790 patients in two cohorts, dropout, biopsy logistics and quarterly cash burn now determine whether the MASH program stays on the communicated timeline.

Future — accelerated-approval step

The study is event-driven with an interim analysis intended to support the accelerated approval pathway, resting on the biopsy endpoint in Cohort 1. Its timing and design have not been detailed separately by the company.

July 2026 — RESTORE enrollment completed

Enrollment in the 48-week alcohol-associated liver disease study closed in July 2026, as reported on August 12, 2026. The protocol was amended so that the primary endpoint, change in liver stiffness measurement, is assessed hierarchically at week 48 and then at week 24. Topline is expected in the second half of 2027.

Pending — RECLAIM peer-reviewed publication or congress presentation

The topline release of July 28, 2026 already carries the treatment effects, p-values, responder rates, PEth, weight and the full adverse-event table. What a publication would add is the confidence intervals, the analysis population and missing-data handling, and independent review.

2029 — anticipated PERFORMA 52-week readout

The long-term anchor remains Phase 3 MASH evidence at 52 weeks in the biopsy cohort. Final approval is expected to rest on liver-related events at approximately 60 months.

05 Company and pipeline snapshot

Altimmune’s pipeline remains concentrated around one molecule across related metabolic, liver and addiction indications. The RECLAIM result broadened clinical validation and the PERFORMA start moved the lead program into late-stage execution, but neither eliminates single-asset risk. A safety, manufacturing, regulatory or pharmacologic problem affecting pemvidutide could still impair every major program.

06 Why pemvidutide may be differentiated — and what still must be proved

Pemvidutide’s defining feature is balanced glucagon and GLP-1 receptor agonism. The company’s development thesis is that GLP-1 activity can support appetite suppression, weight loss and possibly modulation of reward-related behavior, while glucagon activity may contribute more direct effects in the liver. In MASH and alcohol-related disease, that combination could matter because the patient is not defined by a single biomarker: hepatic injury, metabolic dysfunction, obesity, dyslipidemia, hypertension and alcohol exposure may coexist.

RECLAIM gives the thesis its first controlled human validation in AUD. The result shows that the 2.4 mg regimen affected the prospectively defined heavy-drinking-day endpoint beyond placebo. It does not yet establish why the effect occurred. The public topline does not separate central reward-pathway effects from reduced appetite, gastrointestinal tolerability, weight loss, behavioral support or other indirect mechanisms. Mechanism should therefore remain an explanatory hypothesis rather than a claimed clinical fact.

The potential strategic differentiation is the ability to address two layers of disease: the behavior that drives harmful alcohol exposure and the metabolic or hepatic consequences that accompany it. That is precisely why RECLAIM and RESTORE are complementary. A positive AUD signal alone does not prove benefit in alcohol-associated liver disease, and a liver benefit would not automatically prove control of drinking behavior. Together, however, the programs test a more integrated treatment concept than a narrow weight-loss narrative.

Potential advantages

• Positive RECLAIM Phase 2 primary endpoint in AUD.
• Strong MASH-resolution signal in IMPACT.
• Large reductions in liver fat.
• Continued weight and cardiometabolic effects through Week 48.
• Supportive ELF, LSM and qFibrosis analyses.
• Low treatment discontinuation due to adverse events in IMPACT Phase 2b.
• One weekly molecule being studied across behavior, metabolism and liver injury.

Unresolved questions

• RECLAIM reported effect sizes, p-values, responder rates and a full safety table on July 28, 2026, but no confidence intervals and no peer-reviewed publication yet.
• Conventional fibrosis improvement was not statistically significant at Week 24 in IMPACT.
• Digital pathology and non-invasive markers are supportive, not registrational substitutes.
• Phase 3 dose selection, biopsy handling and operational execution will be scrutinized.
• Long-term safety and adherence must hold in larger chronic-treatment populations.
• The AUD result was generated in people with overweight or obesity and may not generalize to all patients.
• Competitive standards may rise before the 2029 MASH readout.

07 IMPACT Phase 2b: the core dataset

IMPACT enrolled 212 participants with biopsy-confirmed MASH and F2 or F3 fibrosis, with and without diabetes. Patients were randomized 1:2:2 to placebo, pemvidutide 1.2 mg or pemvidutide 1.8 mg for 48 weeks. The primary efficacy endpoints were assessed at Week 24.

The dataset was materially positive, especially on MASH resolution, liver fat, weight and tolerability. It was not complete proof of an antifibrotic effect. The conventional fibrosis endpoint remains the principal scientific caveat and the reason that the 48-week non-invasive-marker and digital-pathology analyses are important to the Phase 3 rationale.

08 EASL 2026: liver-marker convergence and cardiometabolic breadth

The EASL package expanded the evidence rather than replacing the original IMPACT readout. At Week 24, 37.8% of patients receiving 1.2 mg and 22.7% receiving 1.8 mg achieved both an ELF reduction greater than 0.5 and an LSM reduction greater than 30%, compared with 8.3% for placebo. In the qFibrosis analysis, 68.6% of the 1.2 mg group and 54.5% of the 1.8 mg group achieved at least one-stage regression versus 29.6% for placebo.

These analyses are useful because they examine overlapping dimensions of disease activity and fibrosis. qFibrosis uses quantitative digital pathology to assess fibrosis across the biopsy specimen, potentially capturing continuous and intra-stage changes that conventional scoring may miss. That does not make qFibrosis equivalent to a registrational endpoint; it makes the total Phase 2 package more biologically coherent.

The Week 48 presentation added cardiometabolic detail. Among patients with elevated baseline lipid values, pemvidutide 1.8 mg produced a 23.7% reduction in triglycerides and a 15.4% reduction in total cholesterol versus placebo. The company also reported 7.5% weight loss without an observed plateau, a 3.0 kg/m² BMI reduction, a 5.3 cm reduction in waist circumference and blood-pressure reductions of 4.0 mmHg systolic and 2.2 mmHg diastolic. Approximately 1% of pemvidutide-treated patients discontinued because of adverse events.

At Week 48, the proportion achieving both at least a 0.5-point ELF reduction and at least a 30% LSM reduction was 3.2% with placebo, 27.8% with 1.2 mg and 32.4% with 1.8 mg. This longer-duration result supports durability and shows a clearer dose relationship than some of the Week 24 exploratory analyses.

The appropriate reading is that EASL strengthened the biological and clinical rationale for PERFORMA. It did not resolve the pivotal risk. Regulators, physicians and payers will evaluate the complete registrational package, including histology, safety, adherence, dosing practicality and any clinical-outcomes component.

09 PERFORMA Phase 3: the main valuation bridge

PERFORMA is a global, randomized, double-blind, placebo-controlled, parallel-group Phase 3 study evaluating the efficacy, safety and clinical outcomes of pemvidutide in adults with MASH and confirmed moderate to advanced liver fibrosis (F2–F3). The design incorporates feedback from the FDA and European regulatory agencies, and patient enrollment began on August 3, 2026.

Regulatory alignment reduces design uncertainty but does not remove execution risk. With the start date now fixed, the monitoring focus shifts to enrollment speed across roughly 1,790 patients in two cohorts, site activation, biopsy logistics, dropout, safety monitoring, the timing and design of the interim analysis, and any change to the expected 2029 readout. MASH trials are expensive and operationally demanding, and a delay of several quarters could materially alter valuation and spending assumptions.

The company’s cash position allows PERFORMA to run from a stronger financial base than many small-cap peers, and management has pointed to a three-month gap between financing the study and enrolling it as evidence of operating discipline. Still, a statement that cash funds operations through an anticipated readout depends on management assumptions. A slower trial, higher site costs, manufacturing changes, expanded programs — including any registrational AUD study that follows the RECLAIM result — or business-development spending could alter the runway.

10 RECLAIM Phase 2: what the July 28 result establishes

RECLAIM was designed to test whether once-weekly pemvidutide could reduce harmful drinking in adults with moderate or severe AUD who also had overweight or obesity. One hundred participants were randomized 1:1 to pemvidutide 2.4 mg or placebo for 24 weeks. The primary endpoint measured the change from baseline in the average number of heavy drinking days per week, using the Timeline Follow-Back method.

Altimmune reported that the primary endpoint was met and that patients receiving pemvidutide reduced heavy drinking days significantly more than patients receiving placebo. That is the most important fact in the disclosure. The trial was randomized, blinded and placebo-controlled, and the primary endpoint had been specified in advance. The result therefore carries more weight than social-media observations, retrospective database studies or open-label anecdotes about patients drinking less while taking GLP-1 therapies.

The result also matters because AUD trials can show large placebo and behavioral-intervention effects. Participants know that drinking is being tracked, attend repeated clinical visits and may receive supportive care. A statistically significant separation from placebo indicates that pemvidutide added an effect beyond those background influences under the study conditions.

What the result does not establish is equally important. RECLAIM is not a Phase 3 trial, does not support approval by itself and does not yet prove that pemvidutide is superior to existing AUD medications or to semaglutide. On abstinence and PEth the release does report results, and both favoured pemvidutide: days of abstinence 38.9% against 20.5% (p=0.0075) and serum PEth -153.4 against +22.0 (p<0.0001). What it does not report is craving, or whether the effect persisted after the drug was stopped: the trial measured 24 weeks on treatment, not what happens afterwards.

11 RECLAIM design: who was studied and what counted as success

The Timeline Follow-Back method is widely used to reconstruct daily drinking, but it depends on patient recall and reporting. That is why the PEth secondary endpoint matters. PEth is a blood biomarker associated with recent alcohol exposure and can provide an objective check on self-reported consumption. A future full-data presentation will be much more persuasive if the heavy-drinking-day result is accompanied by a coherent reduction in PEth.

12 What the topline disclosure confirms—and what remains undisclosed

Confirmed as of July 28

• RECLAIM completed its randomized 24-week comparison.
• Pemvidutide 2.4 mg met the primary endpoint.
• Heavy drinking days fell significantly more than with placebo.
• The studied population had moderate or severe AUD plus overweight or obesity.
• Altimmune plans an FDA meeting to discuss next steps.
• The result supports further development consideration.

Reported on July 28, 2026

• Change in heavy drinking days per week at 24 weeks: -2.75 placebo, -4.20 pemvidutide, LS mean difference -1.45.
• P-value on the primary endpoint: 0.0014.
• WHO risk-level responder rates: 64.4% against 34.8%, odds ratio 3.31, p=0.0049.
• Zero heavy drinking days weeks 21-24: 42.2% against 17.4%, odds ratio 3.84, p=0.0066; days of abstinence 38.9% against 20.5%, p=0.0075.
• PEth: -153.4 against +22.0, difference -175.3, p<0.0001.
• Placebo-adjusted weight change: -9.1%, p<0.0001.

Still not public

• Confidence intervals and the analysis population.
• Missing-data method and sensitivity analyses.
• Craving and total alcohol-consumption measures.
• Weight, BMI and metabolic outcomes.
• Adverse events, serious adverse events and discontinuations.
• Relationship between gastrointestinal effects and drinking reduction.
• Persistence of benefit after treatment ends.

A positive primary endpoint is the correct reason for optimism. The missing details are the correct reason for discipline. A small numerical advantage can be statistically significant without being transformative, while a broad, internally consistent dataset could justify a much larger strategic reassessment. Neither extreme is supported by the data published so far.

13 Why AUD is becoming a serious incretin-development field

The scientific context around RECLAIM is stronger than it was when the trial began. A 2025 randomized study of 48 adults found that low-dose semaglutide reduced alcohol consumed in a laboratory self-administration task, drinks per drinking day and weekly craving, although it did not improve every drinking measure. A larger 2026 randomized trial in 108 treatment-seeking participants with AUD and obesity reported a statistically significant reduction in heavy drinking days with semaglutide 2.4 mg compared with placebo.

The class evidence is not uniformly positive. A randomized 127-patient exenatide trial did not reduce heavy drinking days in the overall population, although exploratory analyses suggested a possible benefit in participants with obesity. That mixed history is relevant. It suggests that molecule, dose, population, weight status, adherence and trial design can materially influence the outcome; a GLP-1 mechanism alone is not a guarantee of success.

RECLAIM therefore adds to an emerging body of controlled evidence rather than creating the field by itself. Pemvidutide’s balanced glucagon component may offer a differentiated liver-metabolic profile, but the current AUD result does not prove that glucagon contributed to the behavioral effect. Comparative or mechanistic evidence would be required to make that claim.

The competitive landscape is also moving toward late-stage testing. The U.S. Department of Veterans Affairs has registered the CRAVE Phase 3 trial of semaglutide in veterans with AUD. If that program proceeds as planned, Altimmune will not develop in an empty field. The company’s opportunity is to move quickly enough to define a credible regulatory path and show that pemvidutide offers clinically useful drinking reduction together with metabolic or liver benefits.

Existing treatment gap

The United States has three FDA-approved AUD medications—naltrexone, acamprosate and disulfiram—but many patients do not receive pharmacotherapy or do not respond adequately.

Class validation

Controlled semaglutide data support the biological concept that incretin therapy can affect drinking behavior in selected populations.

Pemvidutide question

Whether balanced glucagon/GLP-1 activity can produce a differentiated mix of behavioral, metabolic and hepatic benefit.

14 Regulatory path after RECLAIM

Pemvidutide received FDA Fast Track designation for AUD in August 2025. Fast Track can facilitate more frequent interaction with the agency and may allow rolling review or priority review if later requirements are satisfied. It does not lower the evidentiary standard for approval and does not mean that RECLAIM alone is sufficient.

The planned FDA meeting should define the real value of the result. Altimmune will need clarity on whether the agency views heavy drinking days as an acceptable pivotal endpoint in the proposed population, whether WHO risk-level reduction and PEth should be incorporated into the primary or key secondary hierarchy, and whether a single larger study plus confirmatory evidence could be sufficient or two independent pivotal studies will be expected.

Population generalizability will also matter. RECLAIM required overweight or obesity, which fits pemvidutide’s metabolic profile and mirrors other positive incretin-AUD studies. A registrational program may need to determine whether the label should remain limited to this comorbid population or include adults with AUD across a broader BMI range. The answer affects market size, clinical relevance and trial complexity.

Safety will be central because AUD patients may have liver disease, nutritional deficiencies, psychiatric comorbidities, withdrawal risk and use of other medications. Future trials will need to show that weekly pemvidutide can be administered safely and retained in a population that can be more difficult to follow than a conventional obesity cohort.

15 RESTORE Phase 2: the second half of the alcohol-liver strategy

RESTORE evaluates pemvidutide in approximately 120 patients with alcohol-associated liver disease over 48 weeks. Patient enrollment completed in July 2026, ahead of the third quarter guidance the company had previously given. To support future regulatory discussions the protocol was amended: the primary endpoint, change from baseline in liver stiffness measurement, will now be assessed hierarchically at week 48 and then at week 24, with secondary endpoints covering the enhanced liver fibrosis score, alcohol consumption and body weight. Topline data are expected in the second half of 2027. Unlike RECLAIM, which asks whether the drug changes harmful drinking behavior, RESTORE asks whether pemvidutide can improve the liver-related consequences associated with alcohol exposure.

The conceptual link is powerful but should not be overstated. AUD is a behavioral and neuropsychiatric disorder; ALD is an organ-damage spectrum driven by alcohol exposure, inflammation, steatosis and fibrosis. A positive RECLAIM result improves the rationale for studying both ends of that continuum, but it does not predict a positive RESTORE outcome. The populations, endpoints, treatment duration and clinical risks are different.

If both programs ultimately succeed, Altimmune could argue that pemvidutide addresses a uniquely integrated disease pathway: reducing heavy alcohol use while improving metabolic and liver parameters. If RESTORE fails, the AUD result may still stand independently. If RECLAIM’s detailed dataset proves modest but RESTORE shows compelling liver benefit, the strategic emphasis could shift toward organ protection rather than addiction treatment. The two programs should therefore be monitored separately as well as together.

16 Financial position, dilution and warrant structure

Altimmune reported $332.0 million in cash, cash equivalents and short-term investments as of March 31, 2026. After the April offering, the company reported approximately $535 million as of April 30, reflecting the offering’s net proceeds. Q1 research and development expense was $16.2 million, general and administrative expense was $8.1 million, and net loss was $22.6 million, or $0.18 per share.

The April offering generated approximately $225 million in gross proceeds and approximately $211.1 million in net proceeds after underwriting discounts and estimated expenses. It consisted of 64.25 million common shares, pre-funded warrants covering 10.75 million shares, and 75 million accompanying common-stock warrants. The accompanying warrants have a $3.00 exercise price, are immediately exercisable and expire at the earlier of five years after issuance or 45 days following a public announcement of a successful Phase 3 MASH data readout.

The warrant structure creates both financial strength and an overhang. If exercised for cash, the accompanying warrants could provide another $225 million of gross funding. Exercise would also increase the share count substantially. The warrants’ accelerated expiration after a successful Phase 3 announcement may concentrate exercise and trading activity around a future pivotal event.

Altimmune also had $165.3 million remaining under its November 2025 at-the-market program as of March 31, 2026. The stronger cash position may reduce the need to use the ATM in the near term, but the facility remains part of the potential dilution framework.

Second quarter 2026

Altimmune reported $519 million in cash, cash equivalents and investments as of June 30, 2026. Research and development expense was $18.7 million for the quarter against $17.2 million in the same period of 2025, the increase driven by the ongoing ALD trial and by start-up costs for the PERFORMA Phase 3 trial, partly offset by the completion of the IMPACT Phase 2b trial that was still running a year earlier; $11.6 million of that total was direct pemvidutide development cost. General and administrative expense was $7.6 million against $5.7 million, on higher professional services and compensation. Interest income was $4.5 million. The net loss was $22.8 million, or $0.12 per share, against $22.1 million and $0.27 per share a year earlier. The loss itself was slightly larger; the per-share figure improved because the share count more than doubled after the April offering, which is a dilution effect rather than an operating improvement.

Cash consumption is visible across the three reported balance sheet dates: $332.0 million at March 31, 2026, approximately $535 million at April 30 after the offering closed, and $519 million at June 30. Against a quarterly operating cost base of roughly $26.3 million before interest income, and with the deepest phase of PERFORMA spending still ahead, the position funds the programme without removing the question of what happens as Phase 3 enrolment scales.

Constructive interpretation

The company financed a costly pivotal program before the deepest spending phase and says it has runway through the anticipated 52-week data readout. A stronger balance sheet improves execution flexibility and can reduce pressure in partnership discussions.

Cautious interpretation

The financing sharply increased the share-equivalent base and created a large warrant overhang. Capital strength becomes value-creating only if management converts it into timely trial execution and clinically useful milestones.

17 Leadership and operating execution

Jerry Durso became President and Chief Executive Officer effective January 1, 2026 while remaining Chairman. His prior experience includes leading Intercept Pharmaceuticals, a liver-disease company acquired by Alfasigma, and holding senior commercial roles during a long career at Sanofi. That background is relevant as Altimmune moves from mid-stage development into a large, expensive and operationally complex Phase 3 program.

The planned relocation from Gaithersburg, Maryland to Morristown, New Jersey later in 2026 is an operating decision rather than a clinical catalyst. The company said the location should improve access to biopharmaceutical talent, support its hybrid model and create longer-term cost efficiencies. The lease requires approximately $300,000 in annual rent over a five-year term.

The leadership test is concrete: enroll PERFORMA at the communicated pace, recruit and retain the necessary team, manage RECLAIM and RESTORE without overpromising, control spending and communicate clearly as the Phase 3 timeline becomes the dominant driver of the company.

August 13, 2026 — the chief executive buys on the open market. A Form 4 filed the same day reports that President and Chief Executive Officer Jerome Benedict Durso, who also sits on the board, bought 15,000 shares of common stock at 2.95 dollars on August 13, taking his direct holding from 47,500 to 62,500 shares. The transaction carries code P, an open-market purchase, and the filing does not flag it as made under a Rule 10b5-1 plan, so it was discretionary rather than pre-scheduled. About 44,000 dollars is a small sum in absolute terms and proves nothing on its own, but the direction and the timing are worth recording: the purchase came the day after the second-quarter results and the reiteration of the PERFORMA and RESTORE timelines. (Source: SEC Form 4, August 13, 2026)

18 Competitive context

Pemvidutide competes within a rapidly evolving MASH and metabolic market. The relevant landscape includes approved liver-directed therapies, incretin-based medicines, THR-beta agonists, FGF21 analogues and other glucagon-containing combinations. Comparing ALT only with obesity developers such as Viking Therapeutics or Structure Therapeutics misses the company’s intended positioning.

The strategy the company describes is MASH-first with metabolic breadth. Pemvidutide does not need to lead the pure obesity weight-loss race to be clinically important. It does need to show that liver activity, fibrosis evidence, tolerability and cardiometabolic effects combine into a profile that matters to hepatologists, patients and payers.

Competition can validate the market while also increasing the burden of proof. Every successful rival raises expectations for efficacy, safety, convenience, dosing, access and commercial positioning. By the time PERFORMA reads out, the treatment landscape may be materially different from the one in which the trial begins.

Versus obesity incretins

ALT’s case depends on liver differentiation and total metabolic benefit, not simply on maximum weight loss.

Versus liver-directed agents

Pemvidutide aims to combine hepatic and systemic metabolic effects in one weekly therapy.

Versus other MASH pipelines

Success will depend on the total efficacy, safety, dosing and commercial profile rather than any single biomarker.

19 Key risks

• Single-asset concentration: RECLAIM adds a second positive indication, but pemvidutide still drives nearly the entire equity story.
• Incomplete RECLAIM disclosure: effect size, secondary endpoints, PEth, safety and discontinuations remain necessary for a full judgment.
• Phase 2-to-Phase 3 AUD translation: a positive 100-patient study may not reproduce in a larger, broader or longer registrational population.
• AUD placebo and behavioral effects: drinking outcomes can be influenced by trial participation, counseling, recall and retention.
• Population limitation: RECLAIM studied adults with overweight or obesity, so generalizability is unresolved.
• Single-molecule safety linkage: a safety issue in one indication could affect MASH, AUD and ALD development simultaneously.
• MASH Phase 3 translation: positive Phase 2b signals may not reproduce in PERFORMA.
• Fibrosis uncertainty: the conventional Week 24 fibrosis-improvement endpoint did not achieve statistical significance.
• Operational risk: PERFORMA must enroll roughly 1,790 patients across two cohorts and may face site, biopsy, retention, manufacturing or timeline delays.
• Long timeline: the anticipated 52-week MASH readout is not expected until 2029, and final approval is expected to rest on liver-related events at approximately 60 months.
• Capital allocation: advancing AUD after a positive result could increase spending while PERFORMA and RESTORE are also active.
• Dilution: common shares, pre-funded warrants, accompanying warrants, the ATM facility and expanded authorized shares all matter.
• Warrant overhang: 75 million accompanying warrants can influence supply, valuation and trading around future milestones.
• Competition: semaglutide and other incretin programs may establish the AUD standard before pemvidutide reaches late-stage data.
• Regulatory risk: Fast Track and Breakthrough Therapy designations do not guarantee approval or a shortened path.
• Runway assumptions: management’s funding guidance depends on trial timing, cost, scope and whether additional AUD studies are launched.

20 Bull, base and bear framework

Bull case

• Detailed RECLAIM data show a clinically meaningful placebo-adjusted effect, supportive PEth and acceptable safety.
• FDA feedback supports a clear and efficient registrational AUD path.
• PERFORMA enrolls faster than expected and the interim analysis timeline becomes clearer.
• RESTORE, already fully enrolled, retains its patients through the 48-week assessment.
• The MASH liver-metabolic profile remains differentiated as competitors report data.
• The AUD result increases partnering leverage and broadens the strategic value of pemvidutide.
• Cash and potential warrant proceeds support development without near-term financing pressure.

Base case

• RECLAIM is genuinely positive but the effect is moderate and requires a conventional larger Phase 3 program.
• The FDA asks for substantial additional data and broad safety follow-up.
• PERFORMA enrolls at an ordinary pace and the market waits years for validation.
• RESTORE progresses gradually.
• Cash supports operations while dilution and warrants limit the rerating.
• ALT remains a volatile, catalyst-driven single-molecule biotechnology stock.

Bear case

• The Phase 2 effect does not reproduce at Phase 3 scale, or the 10% of patients who stopped the drug for a treatment-related adverse event becomes a larger share in a longer trial.
• FDA feedback requires multiple large and expensive studies.
• PERFORMA enrollment slips or the interim analysis is delayed or fails to support accelerated approval.
• Competitors produce cleaner, faster or commercially stronger AUD and MASH data.
• Capital spending rises as Altimmune tries to fund three development tracks.
• Supportive MASH fibrosis biomarkers fail to translate into Phase 3 histology or outcomes.

21 Timeline

RECLAIM begins

The first participant was enrolled in the randomized 24-week AUD trial.

IMPACT Week 24 data

The primary MASH-resolution endpoint was met; fibrosis improvement numerically favored pemvidutide but was not statistically significant.

RESTORE initiated

The ALD program expanded the serious-liver-disease strategy.

FDA Fast Track in AUD

Pemvidutide received Fast Track designation for alcohol use disorder.

RECLAIM enrollment completed early

One hundred participants were randomized several months ahead of the original schedule.

IMPACT Week 48 update

Longer-duration non-invasive markers, weight loss and tolerability reinforced the Phase 3 MASH rationale.

Breakthrough Therapy Designation and CEO transition

The FDA granted Breakthrough Therapy Designation in MASH, and Jerry Durso assumed the CEO role.

$225 million financing and authorized-share increase

The balance sheet strengthened substantially while the share-equivalent base and warrant overhang increased.

PERFORMA guidance and EASL package

The company detailed the Phase 3 path and presented expanded liver, fibrosis-marker and cardiometabolic analyses.

Headquarters relocation announced

Altimmune announced plans to move its corporate headquarters to Morristown, New Jersey later in 2026.

RECLAIM meets its primary endpoint

Pemvidutide 2.4 mg significantly reduced heavy drinking days compared with placebo in adults with moderate or severe AUD and overweight or obesity.

PERFORMA Phase 3 begins enrolling

The registrational MASH study opened enrollment across two cohorts of approximately 990 and 800 patients, with a 52-week readout anticipated in 2029.

RESTORE enrollment completion expected

Completion of enrollment in the 48-week alcohol-associated liver disease study is the next scheduled operating milestone.

FDA meeting on AUD and full RECLAIM data

The AUD development path will depend on detailed efficacy, biomarker and safety data and on regulatory feedback.

Anticipated PERFORMA 52-week readout

Histology-based evidence from the biopsy cohort, tied to the interim analysis intended to support accelerated approval.

22 Practical monitoring checklist

RECLAIM and AUD development

• Absolute and placebo-adjusted reduction in heavy drinking days.
• P-value, confidence interval and missing-data sensitivity analyses.
• WHO risk-level response and zero-heavy-drinking-day rates.
• PEth biomarker confirmation.
• Craving, total drinking, weight and metabolic outcomes.
• Adverse events, serious adverse events and treatment discontinuations.
• FDA meeting timing and agreed next steps.
• Number, size, duration and population of required pivotal studies.
• Scientific-conference presentation or peer-reviewed publication.

MASH, ALD and operations

• PERFORMA enrollment pace across both cohorts and site activation.
• Timing and design of the interim analysis intended to support accelerated approval.
• Dropout, biopsy logistics and protocol amendments.
• RESTORE enrollment completion and retention.
• Any new liver-safety, gastrointestinal or cardiac-safety findings.
• Changes to the expected 2029 MASH readout.
• Quarterly cash burn as PERFORMA starts.
• Common-share count and warrant exercises.
• Use of remaining ATM capacity.
• Changes to runway guidance.
• Business-development or partnership signals.

23 Merlintrader bottom line

Altimmune is no longer only a MASH execution story with speculative AUD optionality. The July 28 RECLAIM result gives pemvidutide a second positive controlled clinical program and supports the broader thesis that the molecule may operate across metabolism, liver disease and harmful alcohol use. For a company whose value is concentrated in one asset, adding another validated indication is meaningful.

The result should nevertheless be read with discipline. The July 28, 2026 release carries the numbers: an LS mean difference of 1.45 heavy drinking days per week at p=0.0014, two registrational secondary endpoints met, PEth at p<0.0001 and a full safety table. The difference between a useful Phase 2 signal and a genuinely high-value registrational opportunity will now be determined by whether those effects hold at Phase 3 scale, and by FDA feedback at the End-of-Phase 2 meeting. Those are not secondary details; they are the next layer of the thesis.

PERFORMA remains the principal long-term valuation bridge, and as of August 3, 2026 it is running. That retires the risk of a delayed pivotal start and replaces it with a different one: enrolling roughly 1,790 patients across two cohorts, holding retention through biopsy-driven follow-up, and reaching an interim analysis whose timing the company has not described separately. The conventional Week 24 fibrosis endpoint in IMPACT was not statistically significant, MASH Phase 3 execution will be expensive, and the decisive readout remains years away. The April financing gives Altimmune the resources to move forward, but it also created a much larger share-equivalent base and warrant overhang.

The most useful framework after these two announcements is not “the GLP-1 alcohol story has been solved” or “Phase 3 means approval.” It is that the results so far have widened the set of indications the company can credibly pursue, and that the lead programme is now inside the trial that will decide it. Management must prove that the AUD effect is clinically substantial, obtain a workable FDA path, enroll PERFORMA at a credible pace, carry RESTORE through to its week 48 assessment and allocate capital without losing focus. The opportunity has expanded; the evidentiary and execution burden has expanded with it.

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

24 Related Merlintrader coverage

Altimmune research

Altimmune and the obesity-MASH convergence

Altimmune Q4 2025 results and Phase 3 planning

2026 decisive year for IOVA, IBRX and ALT

Sector context

Viking, Structure and Altimmune: the next obesity drug race

Anti-obesity drugs and weight-loss therapies

Free Biotech Catalyst Calendar

Merlintrader Biotech Stock Hubs